---
title: "C&Y Pharmaceutical: Ebastine raw material drug approved for market launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247606497.md"
description: "C&Y Pharmaceutical announced that its subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration to market the raw material drug Ebastine. This medication is suitable for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A., and the Ebastine tablets produced by its subsidiary Hangzhou C&Y Pharmaceutical Co., Ltd. have passed the consistency evaluation and have been included in the National Medical Insurance Catalog Category B"
datetime: "2025-07-08T09:23:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247606497.md)
  - [en](https://longbridge.com/en/news/247606497.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247606497.md)
generator: "portal-rs"
---

# C&Y Pharmaceutical: Ebastine raw material drug approved for market launch

According to the Zhitong Finance APP, C&Y Pharmaceutical (300254.SZ) announced that its subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Ebastine from the National Medical Products Administration.

The announcement shows that Ebastine is suitable for symptomatic treatment of allergic rhinitis (seasonal and perennial) with or without allergic conjunctivitis, and chronic idiopathic urticaria

### Related Stocks

- [300254.CN](https://longbridge.com/en/quote/300254.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)
- [Ata Turizm Discloses High Non-Compliant Income Under Participation Finance Rules](https://longbridge.com/en/news/296522750.md)
- [ANALYSIS-Can nicotine pouches drive Big Tobacco's future beyond cigarettes?](https://longbridge.com/en/news/296178056.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**